Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge
- PMID: 10201942
Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge
Abstract
Intramuscular injection of BALB/c mice with a DNA plasmid encoding nucleoprotein (NP) from influenza virus A/PR/8/34 (H1N1) provides cross-strain protection against lethal challenge with influenza virus A/HK/68 (H3N2). CTL specific for the H-2Kd-restricted epitope NP147-155 are present in these mice and are thought to play a role in the protection. To assess the effectiveness of NP DNA immunization in comparison with influenza virus infection in the induction of CTL responses, we monitored the frequency of CTL precursors (CTLp) in mice following i.m. injection with NP DNA or intranasal infection with influenza virus and showed that the CTLp frequency in NP DNA-immunized mice can reach levels found in mice that had been infected with influenza virus. We also measured the CTLp frequency, anti-NP Ab titers, and T cell proliferative responses in mice that were injected with titrated dosages of NP DNA and documented a correlation of the CTLp frequency and the Ab titers, but not proliferative responses, with the injection dose. Furthermore, we observed a positive correlation between the frequency of NP147-155 epitope-specific CTLp and the extent of protective immunity against cross-strain influenza challenge induced by NP DNA injection. Collectively, these results and our early observations from adoptive transfer experiments of in vitro activated lymphocytes from NP DNA-immunized mice suggest a protective function of NP-specific CTLp in mice against cross-strain influenza virus challenge.
Similar articles
-
Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.J Virol Methods. 2008 Dec;154(1-2):121-7. doi: 10.1016/j.jviromet.2008.08.011. Epub 2008 Sep 27. J Virol Methods. 2008. PMID: 18789973
-
Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.Antiviral Res. 2009 Mar;81(3):253-60. doi: 10.1016/j.antiviral.2008.12.009. Epub 2009 Jan 9. Antiviral Res. 2009. PMID: 19135483
-
Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination.J Immunol. 1998 Mar 1;160(5):2425-32. J Immunol. 1998. PMID: 9498786
-
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.Jpn J Infect Dis. 2000 Dec;53(6):219-28. Jpn J Infect Dis. 2000. PMID: 11227019 Review.
-
The influenza virus-infected host cell, a target for the immune response.Behring Inst Mitt. 1991 Jul;(89):1-11. Behring Inst Mitt. 1991. PMID: 1930089 Review.
Cited by
-
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019. NPJ Vaccines. 2019. PMID: 30701093 Free PMC article.
-
Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.J Biomed Biotechnol. 2011;2011:939860. doi: 10.1155/2011/939860. Epub 2011 Oct 5. J Biomed Biotechnol. 2011. PMID: 22007149 Free PMC article. Review.
-
Controlling influenza by cytotoxic T-cells: calling for help from destroyers.J Biomed Biotechnol. 2010;2010:863985. doi: 10.1155/2010/863985. Epub 2010 May 24. J Biomed Biotechnol. 2010. PMID: 20508820 Free PMC article.
-
New vaccines against influenza virus.Clin Exp Vaccine Res. 2014 Jan;3(1):12-28. doi: 10.7774/cevr.2014.3.1.12. Epub 2013 Dec 18. Clin Exp Vaccine Res. 2014. PMID: 24427759 Free PMC article. Review.
-
Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.Genet Vaccines Ther. 2009 Jun 8;7:7. doi: 10.1186/1479-0556-7-7. Genet Vaccines Ther. 2009. PMID: 19505299 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous